Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Hal Galbraith, PharmD

Senior Director, Clinical Pharmacology
IQVIA

Disclosure(s): No financial relationships to disclose

Poster(s):

594 - An Open-Label Study in Healthy Volunteers to Determine the Absolute Bioavailability of, the Effect of Food and Dosing by Nasogastric Tube upon the Pharmacokinetics of a Single Oral Dose of Olorofim (OLO)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
595 - Olorofim (OLO) for treatment of invasive mould infections in patients with limited or no treatment options: PK data from a Phase 2b open-label study (NCT03583164, Study 32)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET